Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC)

Sadeleştirilmiş öğe sayfası
dc.contributor.authorEralp, Y.
dc.contributor.authorAbdel\\-Razeq, H.
dc.contributor.authorIm, S\\-A.
dc.contributor.authorRihani, J.
dc.contributor.authorLu, Y\\-S.
dc.contributor.authorYap, Y. S.
dc.contributor.authorAzim, H. A.
dc.contributor.authorPrasongsook, N.
dc.contributor.authorZhukova, L.
dc.contributor.authorHu, H.
dc.contributor.authorAlfaro, T. Delgar
dc.contributor.authorWu, J.
dc.contributor.authorGao, M.
dc.contributor.authorEl Saghir, N. S.
dc.date.accessioned2025-10-16T15:14:25Z
dc.date.issued2023
dc.description.abstractCongress of the European-Society-for-Medical-Oncology (ESMO), Madrid, SPAIN, OCT 20-24, 2023
dc.identifier.doi10.1016/j.annonc.2023.09.632
dc.identifier.otherWOS:001087480200444
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6159
dc.publisherELSEVIER
dc.sourceANNALS OF ONCOLOGY
dc.titleQuality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC)
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS